A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin.
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Enzastaurin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PRELUDE
- Sponsors Eli Lilly
- 04 Dec 2018 Results from PRELUDE and one phase 2 trial assessing biomarker potentially predictive of enzastaurin benefit, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 23 May 2016 Results published in the Journal of Clinical Oncology.
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History